Form 4 for ELVN Enliven Therapeutics, Inc.
Accepted 2026-02-19 00:00:00 ET · period of report 2026-02-17 · accession 0001701247-26-000002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-02-19 | 2026-02-17 | ELVN | Collins Helen Louise | Chief MEDICAL Off | S - Sale+OE | $26.17 | -45.0K | 25.0K | -64% | -$1.18M |
| D | 2026-02-19 | 2026-02-17 | ELVN | Collins Helen Louise | Chief MEDICAL Off | M - OptEx | $2.48 | +45.0K | 70.0K | +180% | +$111.6K |
| D | 2026-02-19 | 2026-02-17 | ELVN | Collins Helen Louise | Chief MEDICAL Off | M - OptEx | $0.00 | -45.0K | 221.3K | -17% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-17 | S | D | 45,000 | $26.17 | 25,000 | D | — | — | (F2) This transaction was executed in multiple trades at prices ranging from $25.76 to $26.695. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| 2 | Common | Common Stock | 2026-02-17 | M | A | 45,000 | $2.48 | 70,000 | D | — | — | |
| 3 | Derivative | Stock Option (right to buy) | 2026-02-17 | M | D | 45,000 | $0.00 | 221,268 | D | $2.48 · — to 2031-06-17 | 45,000 Common Stock | (F3) All of the shares subject to this option are fully vested and exercisable as of the date hereof. |